Browse Learn
Pre-Commercial DCF (Pre-Revenue Valuation)
A pre-revenue company has no current product earnings to extrapolate. Start with the development path, then make the cost, timing and commercial assumptions explicit.
Start With the Investment Question
What would need to be true for this asset to justify its implied value? Work backward from that question. A model should expose the assumptions that matter, so a new disclosure can be translated into a revised investment view.
Define the asset, indication, rights owned and next development milestone before building any cash flows.
Build the Cash Flows Before the Valuation
Map preclinical work, clinical development, regulatory review and a potential launch. Place development spending in the years it occurs. Model commercial cash flow from patients, net price, adoption, costs, tax and reinvestment.
High operating margins alone do not establish value. Clinical differentiation and exclusivity must support durable sales, and the model must account for development spending, time and the capital required to reach launch.
Apply Development Risk Explicitly
Risk-adjusted net present value weights each future cash flow by the probability of reaching the state in which it occurs. Development costs and commercial proceeds can therefore have different probability weights.
The probability that the next trial succeeds is not the probability of eventual approval. A later cash flow carries the cumulative probability of every stage before it. Check that development risk is not counted twice: if the explicit probabilities carry it, a higher discount rate for the same risk would count it again.
BioCo: A Simple Starting Example
Assume BioCo has one preclinical asset. To isolate the mechanics, suppose its entire commercial payoff is a single net receipt of $500 million at the end of year 5, with a 10% probability of receiving it. A $20 million development payment is certain and occurs today. Use a 12% annual discount rate.
| Model Component | Assumption / Value |
|---|---|
| Conditional Receipt, Year 5 | $500.00 |
| Probability of Receipt | 10% |
| PV of Expected Receipt | $28.37 |
| Certain Cost Today | −$20.00 |
| Illustrative Asset rNPV | $8.37 |
This is an arithmetic illustration. A full model replaces the single receipt with annual development and commercial cash flows, including conditional future spending and failure scenarios.
What Changes the Answer
| Scenario | Asset rNPV |
|---|---|
| Base case: 10% probability, receipt in year 5, 12% discount rate | $8.37 |
| Probability of receipt 5% | −$5.81 |
| Probability of receipt 15% | $22.56 |
| Receipt in year 7 instead of year 5 | $2.62 |
| Discount rate 10% | $11.05 |
| Discount rate 14% | $5.97 |
At these inputs the asset breaks even at a 7.0% probability of receipt. Probability moves the answer more than the discount rate does: halving it turns the value negative, while a two-point change in the discount rate moves it by $2–3 million. Tie each scenario to the evidence that would make it plausible.
Bridge From Asset Value to Equity Value
Add other asset values and available cash, then subtract debt, corporate overhead and other relevant claims. The treatment must match what is already included in the asset model. Divide by a consistent share count to move from company value to value per share.
Place any financing needed before the next milestone on the same timeline. New shares reduce the ownership, and the value per share, of existing holders.
Interpretation & Common Pitfalls
- Applying one approval probability to every cost, including spending that is already committed.
- Allowing a large addressable market to substitute for a defensible adoption forecast.
- Counting cash or development costs twice when bridging asset value to equity value.
- Treating a single rNPV estimate as more reliable than its underlying assumptions.
Educational content, not investment advice. Terms